A Phase 3 interventional study of Lazertinib 240 mg/160 mg and Gefitinib 250 mg in Non-Small Cell Lung Cancer, sponsored by Yuhan Corporation. Completed at 80 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-29.
Sponsored by Yuhan Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing lazertinib in Carcinoma, Non-Small-Cell Lung — 6 open to participants now, 11 under way, 2 of them phase 3. lazertinib · Carcinoma, Non-Small-Cell Lung.
Among the 20 studies testing lazertinib in Carcinoma, Non-Small-Cell Lung, this one is the 5th largest by enrollment, is one of 2 that started in 2020, is one of 3 in phase 3, and was the 5th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →6 of the 20 studies testing lazertinib in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States, Canada, China and 3 more countries
Ages 18+
Janssen Research & Development, LLC · Sites in United States, Belgium, Finland and 11 more countries
Ages 18+
Sehhoon Park · Sites in Korea, Republic of
Ages 19+
Sung Yong Lee · Sites in Korea, Republic of
Ages 18+
Konkuk University Medical Center · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
lazertinib: first FDA approval 2024 (LAZCLUZE), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 14 · Phase 3 3
First in 2017; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 393 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 67 across the 20 interventional studies. Of the 9 that completed or were terminated, 2 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 20 have an industry lead sponsor. The 10 most frequent:
Yuhan Corporation is the lead sponsor of 110 studies on the registry; 8 are open to participants now.
Yuhan Corporation has 7 studies filed under Carcinoma, Non-Small-Cell Lung — fewer than ten, so there is no comparison to draw.
1 of the studies testing lazertinib in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04077463Janssen Research & Development, LLCA Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer | 2027-02-12 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing lazertinib in Carcinoma, Non-Small-Cell Lung, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase III study will be conducted to evaluate the efficacy and safety of YH25448 as first-line treatment in locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC) patients with EGFR mutations
YH25448 is an oral, highly potent, mutant-selective and irreversible EGFR Tyrosine-kinase inhibitors (TKIs) that targets both the T790M mutation and activating EGFR mutations while sparing wild type EGFR.
This is a Phase III, Randomized, Double-blind study evaluating the efficacy and safety of YH25448 (240 mg orally, once daily) versus Gefitinib (250 mg orally, once daily) in patients with locally advanced or metastatic NSCLC that is known to be EGFR sensitizing mutation (EGFRm) positive, treatment-naïve and eligible for first-line treatment with an EGFR-TKI.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any cardiovascular disease as follows:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lazertinib (240 mg or 160 mg orally, once daily) plus Gefitinib-matching placebo (250 mg orally, once daily) in accordance with the randomization schedule
Drug: Lazertinib 240 mg/160 mg · Drug: Gefitinib-matching placebo 250 mg
Gefitinib (250 mg orally, once daily) plus Lazertinib-matching placebo (240 mg or 160 mg orally, once daily) in accordance with the randomization schedule
Drug: Gefitinib 250 mg · Drug: Lazertinib-matching placebo 240 mg/160 mg
Drug page: Lazertinib
The initial dose of lazertinib 240 mg (3 tablets of 80 mg lazertinib) once daily can be reduced to 160 mg once daily (2 tablets of 80 mg lazertinib) under specific circumstances
Also known as: YH25448 240 mg/160 mg
The initial dose for Gefitinib (250 mg once daily) cannot be reduced to a lower dose
Also known as: Iressa 250 mg
The initial dose of lazertinib-matching placebo 240 mg (3 tablets of 80 mg lazertinib-matching placebo) once daily can be reduced to 160 mg once daily (2 tablets of 80 mg lazertinib-matching placebo) under specific circumstances
Also known as: YH25448-matching placebo 240 mg/160 mg
The initial dose for Gefitinib-matching placebo (250 mg once daily) cannot be reduced to a lower dose
Also known as: Iressa-matching placebo 250 mg
Progression-Free Survival (PFS) According to RECIST v1.1 by Investigator Assessment
PFS was defined as the time from randomization until the date of objective progression or death(by any cause whichever comes first based on investigator assessment using RECIST v1.1 and was used to assess the efficacy of lazertinib compared to the gefitinib).
Time frame: At baseline and every 6 weeks for the first 18 months and then every 12 weeks relative to randomization until progression, assessed up to 29 months per participant.
Objective Response Rate (ORR) According to RECIST v1.1 by Investigator Assessments
ORR was defined as the percentage of participants with measurable disease with at least on visit response of complete response(CR) or Partial response(PR) and it was used to further assess the efficacy of lazertinib compared with gefitinib.
Time frame: At baseline and every 6 weeks for the first 18 months and then every 12 weeks relative to randomization until progression, assessed up to 29 months per participant.
Duration of Response (DoR) According to RECIST v1.1 by Investigator Assessments
DoR was defined as the time from the date of first documented response(CR or PR) until the date of documented progression or death, whichever comes first and was used to further assess the efficacy of lazertinib compared with gefitinib.
Time frame: At baseline and every 6 weeks for the first 18 months and then every 12 weeks relative to randomization until progression, assessed up to 29 months per participant.
Disease Control Rate (DCR) According to RECIST v1.1 by Investigator Assessments
DCR was defined as the percentage of participants who have a best overall response of CR or PR or SD(SD at \>= 6weeks prior to any PD event) and was used to further assess the efficacy of lazertinib compared with gefitinib.
Time frame: At baseline and every 6 weeks for the first 18 months and then every 12 weeks relative to randomization until progression, assessed up to 29 months per participant.
Depth of Response According to RECIST v1.1 by Investigator Assessments
The depth of response was defined as the best percent change in the sum of diameters of target lesions in the absense of new lesions or progression of non-target lesions compared to the baseline and was used to further assess the efficacy of lazertinib compared with gefitinib.
Time frame: At baseline and every 6 weeks for the first 18 months and then every 12 weeks relative to randomization until progression.
Time to Response According to RECIST v1.1 by Investigator Assessments
Time to Response was defined as the time from the date of randomization until the date of first documented response and was used to further assess the efficacy of lazertinib compared with gefitinib.
Time frame: At baseline and every 6 weeks for the first 18 months and then every 12 weeks relative to randomization until progression.
Overall Survival (OS)
OS was defined as the time from the date of randomization until the date of death due to any cause and was used to further assess the efficacy of lazertinib compared with gefitinib.
Time frame: From the randomization to end of study or date of death from any cause, whichever comes first, assessed every 6 weeks. (Up to 29 months per participant.)
Plasma Concentrations of Lazertinib
To characterize the pharmacokinetics (PK) of lazertinib.
Time frame: Blood samples collected from each participant at pre-dose, 1 to 3 hours, and 4 to 6 hours post-dose on Day 1 Cycle 1, Day 1 Cycle 2, Day 1 Cycle 5, Day 1 Cycle 9, and Day 1 Cycle 13.
Cerebrospinal Fluid (CSF) Concentrations of Lazertinib
To characterize the pharmacokinetics (PK) of lazertinib.
Time frame: A cerebrospinal fluid (CSF) sample once collected from participants with brain metastases, at Cycle 5 Day 1 or afterward.
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 Items (QLQ-C30)
The EORTC QLQ-C30 consists of 30 items and measures cancer participants' functioning (health related quality of life (HRQoL)) and symptoms for all cancer types. Questions can be grouped into 5 multi item functional scales (physical, role, emotional, cognitive, and social); 3 multi item symptom scales (fatigue, pain, nausea/vomiting); a 2 item global HRQoL scale; 5 single items assessing additional symptoms commonly reported by cancer participants (dyspnea, loss of appetite, insomnia, constipation, diarrhea) and 1 item on the financial impact of the disease. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. * a high score for a functional scale represents a high / healthy level of functioning * a high score for the global health status / QoL represents a high QoL * but a high score for a symptom scale / item represents a high level of symptomatology / problems
Time frame: Questionnaires completed at Cycle 1 Day1 , Cycle2 Day 1 and then every 6 weeks relative to the randomization date until 28d safety f/u or progression f/u visit(whichever is later).
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaires Lung Cancer 13 Items (EORTC QLQ-LC13)
The EORTC QLQ-LC13 includes questions assessing cough, hemoptysis, dyspnea, site specific pain (symptoms), sore mouth, dysphagia, peripheral neuropathy, and alopecia (treatment related side effects), and pain medication. The items on both measures were scaled and scored using the recommended EORTC procedures. Raw scores were transformed to a linear scale ranging from 0 to 100, with a higher score representing a higher level of functioning or higher level of symptoms. Provided at least half of the items in the scale were completed, the scale score was calculated using only those items for which values existed.
Time frame: Questionnaires completed at Cycle 1 Day1 , Cycle2 Day 1 and then every 6 weeks relative to the randomization date until 28d safety f/u or progression f/u visit(whichever is later).
Change From Baseline in Euro-Quality of Life-5 Dimension-5 Level (EQ-5D-5L)
The EQ-5D comprises the following two questionnaires: * The EQ-5D comprises 5 dimensions of health (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Each dimension comprises five levels (no problems, slight problems, moderate problem, severe problem, unable/extreme problems). * The EQ VAS records the participants self-rated health status on a vertical graduated (0-100) visual analogue scale. The patient's self-rated health is assessed on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state) by the EQ-VAS.
Time frame: Questionnaires completed at Cycle 1 Day1 , Cycle2 Day 1 and then every 6 weeks relative to the randomization date until 28d safety f/u or progression f/u visit(whichever is later).
A total of 393 participants were randomized to treatment at 96 study sites in 13 countries.
| Milestone | Lazertinib 240 mg | Gefitnib 250 mg |
|---|---|---|
| Started | 196 | 197 |
| Completed | 108 | 47 |
| Not completed | 88 | 150 |
| Withdrew: Disease progression | 44 | 109 |
| Withdrew: Adverse event | 19 | 18 |
| Withdrew: Withdrawal by subject | 11 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Death | 12 | 14 |
| Withdrew: Physician decision | 2 | 4 |
| Withdrew: Any reason not specifically recorded | 0 | 2 |
PFS was defined as the time from randomization until the date of objective progression or death(by any cause whichever comes first based on investigator assessment using RECIST v1.1 and was used to assess the efficacy of lazertinib compared to the gefitinib).
| Months | Lazertinib 240 mg | Gefitnib 250 mg |
|---|---|---|
| Progression-Free Survival (PFS) According to RECIST v1.1 by Investigator Assessment | 20.6 (17.8 to 26.1) | 9.7 (9.2 to 11.3) |
ORR was defined as the percentage of participants with measurable disease with at least on visit response of complete response(CR) or Partial response(PR) and it was used to further assess the efficacy of lazertinib compared with gefitinib.
| Percentage of participants | Lazertinib 240 mg | Gefitnib 250 mg |
|---|---|---|
| Objective Response Rate (ORR) According to RECIST v1.1 by Investigator Assessments | 76.0 (69.4 to 81.8) | 76.1 (69.6 to 81.9) |
DoR was defined as the time from the date of first documented response(CR or PR) until the date of documented progression or death, whichever comes first and was used to further assess the efficacy of lazertinib compared with gefitinib.
| Months | Lazertinib 240 mg | Gefitnib 250 mg |
|---|---|---|
| Duration of Response (DoR) According to RECIST v1.1 by Investigator Assessments | 19.4 (16.6 to 24.9) | 8.3 (6.9 to 10.9) |
DCR was defined as the percentage of participants who have a best overall response of CR or PR or SD(SD at \>= 6weeks prior to any PD event) and was used to further assess the efficacy of lazertinib compared with gefitinib.
| Percentage of participants | Lazertinib 240 mg | Gefitnib 250 mg |
|---|---|---|
| Disease Control Rate (DCR) According to RECIST v1.1 by Investigator Assessments | 93.9 (89.5 to 96.8) | 93.9 (89.6 to 96.8) |
The depth of response was defined as the best percent change in the sum of diameters of target lesions in the absense of new lesions or progression of non-target lesions compared to the baseline and was used to further assess the efficacy of lazertinib compared with gefitinib.
Results for this outcome have not been posted.
Time to Response was defined as the time from the date of randomization until the date of first documented response and was used to further assess the efficacy of lazertinib compared with gefitinib.
Results for this outcome have not been posted.
OS was defined as the time from the date of randomization until the date of death due to any cause and was used to further assess the efficacy of lazertinib compared with gefitinib.
| Participants | Lazertinib 240 mg | Gefitnib 250 mg |
|---|---|---|
| Death | 49 | 64 |
| Alive/Censored | 147 | 133 |
To characterize the pharmacokinetics (PK) of lazertinib.
Results for this outcome have not been posted.
To characterize the pharmacokinetics (PK) of lazertinib.
Results for this outcome have not been posted.
The EORTC QLQ-C30 consists of 30 items and measures cancer participants' functioning (health related quality of life (HRQoL)) and symptoms for all cancer types. Questions can be grouped into 5 multi item functional scales (physical, role, emotional, cognitive, and social); 3 multi item symptom scales (fatigue, pain, nausea/vomiting); a 2 item global HRQoL scale; 5 single items assessing additional symptoms commonly reported by cancer participants (dyspnea, loss of appetite, insomnia, constipation, diarrhea) and 1 item on the financial impact of the disease. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. * a high score for a functional scale represents a high / healthy level of functioning * a high score for the global health status / QoL represents a high QoL * but a high score for a symptom scale / item represents a high level of symptomatology / problems
Results for this outcome have not been posted.
The EORTC QLQ-LC13 includes questions assessing cough, hemoptysis, dyspnea, site specific pain (symptoms), sore mouth, dysphagia, peripheral neuropathy, and alopecia (treatment related side effects), and pain medication. The items on both measures were scaled and scored using the recommended EORTC procedures. Raw scores were transformed to a linear scale ranging from 0 to 100, with a higher score representing a higher level of functioning or higher level of symptoms. Provided at least half of the items in the scale were completed, the scale score was calculated using only those items for which values existed.
Results for this outcome have not been posted.
The EQ-5D comprises the following two questionnaires: * The EQ-5D comprises 5 dimensions of health (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Each dimension comprises five levels (no problems, slight problems, moderate problem, severe problem, unable/extreme problems). * The EQ VAS records the participants self-rated health status on a vertical graduated (0-100) visual analogue scale. The patient's self-rated health is assessed on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state) by the EQ-VAS.
Results for this outcome have not been posted.
Collected over All adverse events (AEs) were collected from the time of signature of informed consent throughout the Treatment Period and including the safety follow-up period.The safety follow-up period was defined as 28 days after study drug was discontinued. (Up to 29 months per participant.). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lazertinib 240 mg | 49/196 (25%) | 51/196 (26%) | 189/196 (96.4%) |
| Gefitnib 250 mg | 64/197 (32.5%) | 51/197 (25.9%) | 188/197 (95.4%) |
| Event | Lazertinib 240 mg | Gefitnib 250 mg |
|---|---|---|
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 8/196 | 2/197 |
| PneumoniaInfections and infestations | 8/196 | 3/197 |
| Acute kidney injuryRenal and urinary disorders | 1/196 | 4/197 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 3/196 | 1/197 |
| DiarrhoeaGastrointestinal disorders | 3/196 | 1/197 |
| DeathGeneral disorders | 3/196 | 3/197 |
| COVID-19Infections and infestations | 1/196 | 3/197 |
| Pneumocystis jirovecii pneumoniaInfections and infestations | 0/196 | 3/197 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 2/196 | 1/197 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/196 | 0/197 |
| Event | Lazertinib 240 mg | Gefitnib 250 mg |
|---|---|---|
| ParaesthesiaNervous system disorders | 77/196 | 13/197 |
| DiarrhoeaGastrointestinal disorders | 51/196 | 77/197 |
| RashSkin and subcutaneous tissue disorders | 71/196 | 72/197 |
| Alanine aminotransferase increasedInvestigations | 30/196 | 59/197 |
| PruritusSkin and subcutaneous tissue disorders | 52/196 | 36/197 |
| Aspartate aminotransferase increasedInvestigations | 22/196 | 52/197 |
| AnaemiaBlood and lymphatic system disorders | 36/196 | 23/197 |
| ParonychiaSkin and subcutaneous tissue disorders | 35/196 | 34/197 |
| Decreased appetiteMetabolism and nutrition disorders | 33/196 | 31/197 |
| StomatitisGastrointestinal disorders | 31/196 | 16/197 |
The full analysis set (FAS), FAS included all randomized participants.
| Age, Customized(years) | Lazertinib 240 mg | Gefitnib 250 mg | Total |
|---|---|---|---|
| Median | 67 (31 to 87) | 64 (25 to 86) | 65 (25 to 87) |
| Sex: Female, Male(Participants) | Lazertinib 240 mg | Gefitnib 250 mg | Total |
|---|---|---|---|
| Female | 132 | 119 | 251 |
| Male | 64 | 78 | 142 |
| Race/Ethnicity, Customized(Participants) | Lazertinib 240 mg | Gefitnib 250 mg | Total |
|---|---|---|---|
| Race — Asian | 130 | 130 | 260 |
| Race — Non-Asian | 66 | 67 | 133 |
| Smoking history(Participants) | Lazertinib 240 mg | Gefitnib 250 mg | Total |
|---|---|---|---|
| Never | 135 | 149 | 284 |
| Former | 50 | 42 | 92 |
| Current | 11 | 6 | 17 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual participant data (including data dictionaries) that underline the results reported in study-related publications will be made available during the period beginning 1 year and ending 5 years after all trial primary and secondary endpoints were assessed. Only requests from researchers who provide a methodologically sound proposal will be reviewed and approved by the sponsor. The analysis type should be in accordance with aims in the proposal approved by the sponsor. Proposals should be directed to hmbyun@yuhan.co.kr. Other documents(i.e. a summary of the study results, study protocol, statistical analysis plan) will be posted in the publicly accessible database (i.e. clinicaltrials.gov) no later than 1 year after the study's primary completion date.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Beginning 1 year and ending 5 years after all trial primary and secondary endpoints were assessed.
Access criteria: Only requests from researchers who provide a methodologically sound proposal will be reviewed and approved by the sponsor. The analysis type should be in accordance with aims in the proposal approved by the sponsor. Proposals should be directed to hmbyun@yuhan.co.kr.
Ran from Feb 2020 to primary completion in Jul 2022, 29 months.
Results were first posted in Mar 2024, 1 year 7 months after primary completion.
Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 29 months is below that.
Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lazertinib
Carcinoma, Non-Small-Cell Lung →